TWI786742B - 吡啶酮類化合物及其製備方法和應用 - Google Patents

吡啶酮類化合物及其製備方法和應用 Download PDF

Info

Publication number
TWI786742B
TWI786742B TW110127160A TW110127160A TWI786742B TW I786742 B TWI786742 B TW I786742B TW 110127160 A TW110127160 A TW 110127160A TW 110127160 A TW110127160 A TW 110127160A TW I786742 B TWI786742 B TW I786742B
Authority
TW
Taiwan
Prior art keywords
alkyl
compound
substituted
group
cancer
Prior art date
Application number
TW110127160A
Other languages
English (en)
Chinese (zh)
Other versions
TW202210460A (zh
Inventor
程輝敏
温曉明
劉志強
張國剛
魏勇
齊珍珍
牛春意
張佩宇
賴力鵬
馬健
温書豪
Original Assignee
大陸商深圳晶泰科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商深圳晶泰科技有限公司 filed Critical 大陸商深圳晶泰科技有限公司
Publication of TW202210460A publication Critical patent/TW202210460A/zh
Application granted granted Critical
Publication of TWI786742B publication Critical patent/TWI786742B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/69Two or more oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
TW110127160A 2020-07-23 2021-07-23 吡啶酮類化合物及其製備方法和應用 TWI786742B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010719751 2020-07-23
CN202010719751.4 2020-07-23

Publications (2)

Publication Number Publication Date
TW202210460A TW202210460A (zh) 2022-03-16
TWI786742B true TWI786742B (zh) 2022-12-11

Family

ID=79728529

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110127160A TWI786742B (zh) 2020-07-23 2021-07-23 吡啶酮類化合物及其製備方法和應用

Country Status (3)

Country Link
CN (1) CN115803316A (fr)
TW (1) TWI786742B (fr)
WO (1) WO2022017524A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200626576A (en) * 2004-09-15 2006-08-01 Novartis Ag Bicyclic amides as kinase inhibitors
US20110034461A1 (en) * 2008-02-05 2011-02-10 Sanofi-Aventis Sf5 derivatives as par1 inhibitors, production thereof, and use as medicaments
CN105051027A (zh) * 2013-03-15 2015-11-11 葛兰素史密斯克莱知识产权发展有限公司 作为转染期间重排(ret)激酶抑制剂的吡啶衍生物
CN107074768A (zh) * 2014-09-10 2017-08-18 葛兰素史克知识产权发展有限公司 作为转染重排(ret)激酶抑制剂的吡啶酮衍生物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2587207A1 (fr) * 2004-11-23 2006-06-01 Merck & Co., Inc. Agonistes des recepteurs de la niacine, compositions contenant ces composes et methodes de traitement
ES2691227T3 (es) * 2014-10-16 2018-11-26 Bayer Pharma Aktiengesellschaft Derivados fluorados de benzofuranil-pirimidina que contienen un grupo sulfoximina

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200626576A (en) * 2004-09-15 2006-08-01 Novartis Ag Bicyclic amides as kinase inhibitors
US20110034461A1 (en) * 2008-02-05 2011-02-10 Sanofi-Aventis Sf5 derivatives as par1 inhibitors, production thereof, and use as medicaments
CN105051027A (zh) * 2013-03-15 2015-11-11 葛兰素史密斯克莱知识产权发展有限公司 作为转染期间重排(ret)激酶抑制剂的吡啶衍生物
CN107074768A (zh) * 2014-09-10 2017-08-18 葛兰素史克知识产权发展有限公司 作为转染重排(ret)激酶抑制剂的吡啶酮衍生物

Also Published As

Publication number Publication date
WO2022017524A1 (fr) 2022-01-27
TW202210460A (zh) 2022-03-16
CN115803316A (zh) 2023-03-14

Similar Documents

Publication Publication Date Title
JP6782255B2 (ja) ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法
CN102459187B (zh) Janus激酶抑制化合物和方法
TW202128691A (zh) Kras 突變蛋白抑制劑
JP7046940B2 (ja) 神経栄養因子チロシンキナーゼ受容体阻害剤として用いられるアミノピラゾロピリミジン化合物
JP6139789B2 (ja) 縮合複素環化合物、その調製方法、医薬組成物及びその使用
JP7331212B2 (ja) フェニル-2-ヒドロキシ-アセチルアミノ-2-メチル-フェニル化合物
CA3088927A1 (fr) Derive de biaryle, procede de preparation et usage pharmaceutique associes
WO2018225093A1 (fr) Composés chimiques utilisés comme inhibiteurs de la voie atf4
TW200806675A (en) Heterobicyclic thiophene compounds and methods of use
CA2908098A1 (fr) Inhibiteurs mk2 et utilisations associees
JP2023535746A (ja) Cdk7キナーゼ阻害剤として使用される化合物およびその適用
EP3470409A1 (fr) Composes dérivés de benzotriazole a et b amide non satures utilises comme inhibiteurs de tgf-br1
EP2949647A1 (fr) Composé d'aminopyrimidine phényle deutérié et composition pharmaceutique le contenant
JP2022502444A (ja) 3−アザビシクロ[3,1,1]ヘプタン誘導体及びこれを含む薬学的組成物
TW201103894A (en) 4-substituted pyridazinone compound and p2x7 receptor inhibitor
CN113164475A (zh) Dyrk1a的大环抑制剂
EP4074710A1 (fr) Composé de pyrazolo[1,5-a]pyridine, son procédé de préparation et son utilisation
TW202043232A (zh) Pde9抑制劑及其用途
TW202035408A (zh) 三環janus 激酶1 抑制劑及其組合物和方法
JP2021501215A (ja) アミノ置換窒素含有縮合環化合物、その調製方法及び使用
CN110028507A (zh) 具有trk激酶抑制活性化合物、制备方法、组合物及用途
TW200936579A (en) Cycloalkyloxy-and heterocycloalkyloxypyridine compounds as modulators of the histamine H3 receptor
KR20230043885A (ko) 트리시클릭 헤테로사이클
WO2021099832A2 (fr) Composés antagonistes des récepteurs de l'adénosine
CN110804059B (zh) 氨基甲酸酯类化合物、药物组合物及其应用